Skip to main content
PEPTARA LABS
Get Started

Research reference

CJC-1295 Ipamorelin Research: What Studies Measured

Published by · Updated · How we research and check our pages

The short answer

CJC-1295 ipamorelin research has set no value for the blend, because no published human trial has ever tested CJC-1295 and ipamorelin together. What exists is one compound at a time. CJC-1295 was given under the skin to healthy adults in two randomized, placebo-controlled trials, single doses at rising levels in the first and repeated doses in the second, and was reported as safe and relatively well tolerated (Teichman et al., JCEM 2006, PMID 16352683). A second research group gave healthy men a single injection and tracked their growth hormone for a full week afterward (Ionescu and Frohman, JCEM 2006, PMID 17018654). Ipamorelin has been given to healthy male volunteers in one small study of several dose levels, with eight men at each level (Gobburu et al., Pharm Res 1999, PMID 10496658); its other widely quoted figures come from animal potency work in rats and swine (Raun et al., Eur J Endocrinol 1998, PMID 9849822). We leave the trial amounts off this page on purpose. They were worked out per kilogram for small groups of screened, healthy volunteers watched by study staff, neither compound is an approved medicine, and Peptara Labs supplies both only as research material for lab use. A personal decision belongs with a qualified clinician.

General educational information, research-use framing only, not medical advice. Neither compound is an approved medicine, and any decision about a research compound belongs with a qualified clinician.

What the research reports

Two kinds of data sit behind this question and mixing them up is the most common error online. CJC-1295 has human trials that measured hormone responses in healthy adults. Ipamorelin has an animal pharmacology paper that reports potency as an ED50 in nanomoles per kilogram. An ED50 is not a dose, the units are not interchangeable, and no study combined the two compounds. The Model column below is where that distinction lives.

CompoundModelProtocol the study ranWhat it measuredSource
CJC-1295 (albumin-binding form)Healthy adults, ages 21 to 61Subcutaneous; randomized, placebo-controlled, double-blind; single doses at several rising levels in the first trial, then repeated doses in the secondMean plasma GH rose 2 to 10 fold for 6 days or more; mean plasma IGF-1 rose 1.5 to 3 fold for 9 to 11 days; estimated half-life 5.8 to 8.1 daysTeichman et al., JCEM 2006, PMID 16352683
CJC-1295 (albumin-binding form)Healthy men, ages 20 to 40Single injection, two dose groups comparedTrough GH up 7.5 fold, mean GH up 46 percent, IGF-1 up 45 percent, GH pulse frequency and magnitude unchanged; no significant difference between the two dosesIonescu and Frohman, JCEM 2006, PMID 17018654
IpamorelinAnaesthetised rats and conscious swine (animal pharmacology)Dose-response assay reporting ED50, the dose producing half the maximum GH responseAn ED50 in each species, with swine far more sensitive than rats; no ACTH or cortisol rise beyond that seen with GHRH, even at doses far above the GH ED50Raun et al., Eur J Endocrinol 1998, PMID 9849822
IpamorelinHealthy male volunteers, eight at each dose levelShort infusions at a series of rising dose levelsDose-proportional pharmacokinetics, terminal half-life about 2 hours, a single episode of GH release peaking near 0.67 hours, and an SC50 of 214 nmol/L for half-maximal GH stimulationGobburu et al., Pharm Res 1999, PMID 10496658

Two things the table makes plain. The CJC-1295 trials scaled their amounts to body weight, so no single fixed number describes how either trial was run. The ipamorelin ED50 row is animal potency work, which measures how potent the molecule is rather than how much of it a person was given, while the row below it is one human pharmacokinetic study of how the body handled the peptide. Reconstitution is a separate thing and is lab arithmetic: the Peptara Labs reference is 2 ml of bacteriostatic water for every vial, so the concentration in mg per mL is the vial strength in mg divided by 2. The peptide reconstitution calculator runs that concentration math for any vial strength and any volume you enter.

DAC and no DAC are not the same compound

This is the distinction that decides everything else on the page, and it is the one most often skipped. DAC stands for drug affinity complex. It is a chemical group attached to the peptide whose only job is to bind albumin, the most abundant protein in blood, so the molecule stays in circulation instead of clearing in minutes.

With DAC

The form the human trials used

Ionescu and Frohman describe the analog as binding permanently to endogenous albumin after injection, with a half-life of 8 days (JCEM 2006, PMID 17018654). Teichman et al. estimated 5.8 to 8.1 days, and reported that a single injection raised mean GH 2 to 10 fold for 6 days or more and IGF-1 1.5 to 3 fold for 9 to 11 days, with IGF-1 staying above baseline for up to 28 days after repeat dosing (JCEM 2006, PMID 16352683). That long persistence is what shaped the design of the repeat-dose arm. Every human CJC-1295 result quoted anywhere on this page comes from this form.

Without DAC

A short-acting fragment with no dose-finding trial

Remove the albumin-binding complex and the albumin binding goes with it, so the multi-day persistence that defines the trial data is simply not there. What remains is a short-acting GHRH-type peptide. We have not found a published human dose-finding trial of the non-DAC form, so there is no protocol to report for it and no basis for carrying the long-acting trial design across. Anyone quoting a precise non-DAC protocol as research-backed is quoting something other than the published record.

The practical consequence is that a source discussing CJC-1295 without naming the form is not a usable source, because the same name covers two molecules with different pharmacokinetics. Ipamorelin sits outside this split entirely: it is a short-acting pentapeptide that acts through a GHRP-like receptor rather than the GHRH receptor (Raun et al., Eur J Endocrinol 1998, PMID 9849822), which is why the two are discussed side by side even though no published study combined them. For the pharmacokinetics on their own, see the half-life breakdown, and for what Peptara publishes about the blend it sells, including batch certificates, see the CJC-1295 / Ipamorelin product page.

What CJC-1295 before and after actually tracks in studies

Searches for before-and-after results expect photographs. The published record has none, and the reason is worth stating precisely: the CJC-1295 trials never measured body composition. Teichman et al. measured peak concentrations and area under the curve for GH and IGF-1 (JCEM 2006, PMID 16352683). Ionescu and Frohman measured GH pulse frequency, trough and mean GH, and IGF-1 across an overnight sampling window (JCEM 2006, PMID 17018654). No scan, no scale, no photograph. So the honest answer to what CJC-1295 before and after shows is that the trials did not look.

That is not the same as saying nothing in this drug class has ever been measured properly. Two trials on related GH-axis compounds show what a real before-and-after endpoint looks like, and both are instructive precisely because they are unflattering.

Imaging, a control arm, and a percentage

A GHRH-analog trial randomized 412 patients to a subcutaneous injection or placebo for 26 weeks, with the primary endpoint being percent change from baseline in visceral adipose tissue on computed tomography. Visceral adipose tissue fell 15.2 percent on the active arm and rose 5.0 percent on placebo, and IGF-1 rose 81.0 percent (Falutz et al., NEJM 2007, PMID 18057338). The number means something because a scanner produced it and a placebo group sat beside it.

And what careful measurement often finds

A two-year randomized trial of an oral ghrelin mimetic in 65 healthy adults aged 60 to 81 measured fat-free mass and abdominal visceral fat as its primary endpoints at 12 months. Fat-free mass rose 1.1 kg on the active arm against a 0.5 kg fall on placebo. But there was no significant difference in abdominal visceral fat or total fat mass, body weight rose 2.7 kg, fasting glucose rose and insulin sensitivity fell, and the authors recorded that the increased fat-free mass did not translate into any change in strength or function (Nass et al., Ann Intern Med 2008, PMID 18981485).

That last finding is the whole point. A GH secretagogue moved a body-composition number in the expected direction and the people taking it were not measurably stronger. A before-and-after photograph cannot distinguish 1.1 kg of fat-free mass from water retention, a different camera angle, or twelve months of training, which is why the trials that wanted an answer used scanners and control groups instead.

Where both compounds stand with the FDA

Neither is an approved drug. Both are named on the FDA page covering bulk drug substances that may present significant safety risks in compounding, but they sit in two different tables on it and the difference is worth stating exactly.

Ipamorelin acetate is in the current category 2 table, marked 503B, added 29 September 2023. The agency records immunogenicity risk from aggregation or peptide-related impurities, unnatural amino acids that complicate characterization, and a study in the literature reporting serious adverse events including death when ipamorelin was administered intravenously to improve gastric motility.

CJC-1295 is in the second table, which the FDA describes as substances previously in category 2 of the interim policies whose nominations were withdrawn by the nominators. The agency's recorded concerns still stand against it there: that compounded drugs containing CJC-1295 may pose a risk for immunogenicity by certain routes of administration, that it has identified serious adverse events including increased heart rate and systemic vasodilatory reaction, and that available clinical data are limited. So the accurate statement is that the FDA documented those concerns and the nomination was later withdrawn, not that CJC-1295 sits on a current category 2 list. Both entries were read directly from the FDA page on 29 August 2026.

This matters for reading the rest of the page correctly. Research-reported hormone responses and a regulator flagging safety questions are both true at once, and neither cancels the other out. See are peptides legal for how research-use status works more broadly.

CJC-1295 ipamorelin research: FAQ

Is there a standard CJC-1295 ipamorelin dosage?

No. No published human trial has tested the two peptides together as a fixed combination, so there is no standard dose for the pair and no regulator has set one. Every honest data point comes from one compound studied on its own: CJC-1295 in trials that compared several dose levels in healthy adults aged 21 to 61 (Teichman et al., JCEM 2006, PMID 16352683) and in a single-injection trial in healthy men aged 20 to 40 (Ionescu and Frohman, JCEM 2006, PMID 17018654), and ipamorelin in one small human study that compared several dose levels in groups of eight men (Gobburu et al., Pharm Res 1999, PMID 10496658) alongside animal potency work in rats and swine (Raun et al., Eur J Endocrinol 1998, PMID 9849822). A precise blend protocol presented as settled science is going past the published record.

Is CJC-1295 with DAC dosed differently?

In the published research the two forms are not interchangeable, and the reason is pharmacokinetic rather than a matter of preference. The form studied in humans carries a drug affinity complex that binds permanently to circulating albumin after injection, which is what produced an estimated half-life of 5.8 to 8.1 days (Teichman et al., JCEM 2006, PMID 16352683) and a reported half-life of about 8 days (Ionescu and Frohman, JCEM 2006, PMID 17018654). That long persistence shaped how the second Teichman trial spaced its repeat doses, and it is why the Ionescu trial could sample a full week after one injection and still see an effect. Strip the albumin-binding complex out and you are left with a short-acting GHRH fragment that does not carry that extension, so nothing learned from the long-acting trials transfers to it. There is no published human dose-finding trial of the non-DAC form, which is the honest limit of what can be said here. This describes what the trials did. It is not a schedule for anyone to follow.

What did the CJC-1295 human trials actually measure?

Blood hormone concentrations and tolerability, not body composition. Teichman et al. measured peak concentrations and area under the curve for GH and IGF-1 across two randomized, placebo-controlled, double-blind trials of several dose levels lasting 28 and 49 days, and reported the compound as safe and relatively well tolerated (JCEM 2006, PMID 16352683). Ionescu and Frohman sampled blood at 20-minute intervals over a 12-hour overnight window to see whether GH pulsatility survived continuous stimulation, and found that it did (JCEM 2006, PMID 17018654). Neither trial weighed anyone, scanned anyone, or measured fat or muscle.

What do CJC-1295 before and after results show in research?

Nothing, because no published CJC-1295 or ipamorelin trial measured a before-and-after change in body composition. The trials measured hormones. For contrast, studies that did measure body composition in this drug class used imaging and a placebo arm: a GHRH analog trial in 412 patients used CT to track visceral adipose tissue over 26 weeks and reported a 15.2 percent decrease against a 5.0 percent increase on placebo (Falutz et al., NEJM 2007, PMID 18057338), and a two-year trial of an oral ghrelin mimetic in 65 adults aged 60 to 81 reported fat-free mass over 12 months rising 1.1 kg against a 0.5 kg fall on placebo, with no significant difference in abdominal visceral fat or total fat mass and no change in strength or function (Nass et al., Ann Intern Med 2008, PMID 18981485). That is what a measured before and after looks like, and it is not what a photograph is.

How did the ipamorelin studies measure dose?

By body weight, in a molar unit rather than in micrograms, in both the animal potency work and the human study. Raun et al. characterized ipamorelin by ED50, the dose producing half of the maximum GH response, in anaesthetised rats and conscious swine, because that is how a potency comparison against other secretagogues is made (Eur J Endocrinol 1998, PMID 9849822). The human pharmacokinetic study used the same kind of unit (Gobburu et al., Pharm Res 1999, PMID 10496658). An ED50 measured in swine is a property of the molecule, not an instruction for a person, and turning any study figure into a human microgram amount requires assumptions neither paper made.

Are CJC-1295 and ipamorelin approved drugs?

No. Neither is an approved medicine, and both are named on the FDA page covering bulk drug substances that may present significant safety risks in compounding, though in two different tables. Ipamorelin acetate is in the current category 2 table, marked 503B and added 29 September 2023, where the agency notes immunogenicity risk, unnatural amino acids that complicate characterization, and a published report of serious adverse events including death when ipamorelin was given intravenously for gastric motility. CJC-1295 is in the second table, which the FDA describes as substances previously in category 2 whose nominations were withdrawn by the nominators; the recorded concerns there are immunogenicity by certain routes, serious adverse events including increased heart rate and systemic vasodilatory reaction, and limited available clinical data (FDA, Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks, read 29 August 2026).

References

  1. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults." Journal of Clinical Endocrinology and Metabolism. 2006;91(3):799-805. PMID: 16352683.
  2. Ionescu M, Frohman LA. "Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog." Journal of Clinical Endocrinology and Metabolism. 2006;91(12):4792-4797. PMID: 17018654. doi:10.1210/jc.2006-1702.
  3. Raun K, Hansen BS, Johansen NL, Thogersen H, Madsen K, Ankersen M, Andersen PH. "Ipamorelin, the first selective growth hormone secretagogue." European Journal of Endocrinology. 1998;139(5):552-561. PMID: 9849822.
  4. Gobburu JV, Agerso H, Jusko WJ, Ynddal L. "Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers." Pharmaceutical Research. 1999;16(9):1412-1416. PMID: 10496658.
  5. Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, et al. "Metabolic effects of a growth hormone-releasing factor in patients with HIV." New England Journal of Medicine. 2007;357(23):2359-2370. PMID: 18057338.
  6. Nass R, Pezzoli SS, Oliveri MC, Patrie JT, Harrell FE, Clasey JL, et al. "Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial." Annals of Internal Medicine. 2008;149(9):601-611. PMID: 18981485.
  7. U.S. Food and Drug Administration. "Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks." https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks

General educational information only, research-use framing, not medical advice. Every result above is what a named study measured in its own subjects, reported as such. None of it is a recommendation. Consult a qualified professional before acting.

Chat with us